AT 501

Drug Profile

AT 501

Alternative Names: AT501; H7N9 influenza vaccine - Medigen Vaccinology

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator National Health Research Institutes
  • Developer Medigen Vaccinology Corp
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza A virus H7N9 subtype

Most Recent Events

  • 01 Feb 2016 Medigen completes phase-I/II clinical trials in Influenza-A virus H7N9 subtype (Prevention, In adults) in Taiwan (Parenteral) (NCT02436928)
  • 01 Apr 2015 Phase-I/II clinical trials in Influenza-A virus H7N9 subtype (Prevention, In adults) in Taiwan (Parenteral) (NCT02436928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top